Summary
Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies.
Source: Reuters
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
